Clinical Trial Update: Safety Study of Recombinant Vaccine to Prevent ETEC Diarrhea [Phase 1]

View source ↗

Summary

Phase 1 safety study of a recombinant vaccine intended to prevent diarrhea caused by Enterotoxigenic Escherichia coli (ETEC) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Enterotoxigenic Escherichia Coli Infection

Drugs mentioned

• Enterotoxigenic Escherichia coli recombinant vaccine (recombinant ETEC vaccine)

Snippet

Sponsor: U.S. Army Medical Research and Development Command | Conditions: Escherichia Coli Infection | Phase 1 | Status: COMPLETED